For China's chronic rhinosinusitis with nasal polyps (CRSwNP) community, the approval of depemokimab marks a shift from repeated symptom control toward long-term inflammatory disease management. The National Medical Products Administration has approved the GSK biologic, in combination with intranasal corticosteroids, for adults whose disease remains uncontrolled after surgery and/or systemic corticosteroid therapy.
The need is substantial. An expert consensus on biologic therapy for CRSwNP estimates that China has about 38 million patients with the condition, and nearly half fail to achieve satisfactory disease control even after standardized medical and surgical treatment. These patients often live with persistent nasal obstruction, impaired smell, facial pain, sleep disturbance, and repeated infections.
Why conventional treatment reaches a ceiling
CRSwNP is driven by chronic inflammation of the nasal and sinus mucosa. Intranasal corticosteroids remain first-line therapy and can reduce mucosal edema and polyp size in milder disease, but they are often insufficient for moderate-to-severe or extensive polyps. Short courses of oral corticosteroids can shrink polyps quickly, yet relapse after discontinuation is common; prolonged systemic exposure can cause hyperglycemia, osteoporosis, gastrointestinal adverse effects, and immunosuppression.
Endoscopic sinus surgery improves ventilation and drainage by opening sinus ostia and removing polyps, but it cannot remove the underlying inflammatory environment. Dr. Anhai Chen of the First Affiliated Hospital, Sun Yat-sen University, told MedJ that surgery addresses the visible lesion and structure, while persistent type 2 inflammation can continue to drive new polyp growth. Patients with eosinophilic polyps and comorbid asthma are especially prone to recurrence, sometimes entering a cycle of surgery, relapse, and reoperation.
This is the clinical gap biologics are designed to address. Instead of broadly suppressing inflammation or physically removing tissue, targeted antibodies aim at the immune pathways that sustain the disease. In practice, physicians often consider a biologic when first- and second-line strategies fail, particularly in patients with a long disease history, recurrent polyps, asthma, or risk factors that make repeated steroid exposure undesirable.
A longer-interval IL-5 strategy
Depemokimab is a humanized monoclonal antibody that targets interleukin-5, a central cytokine for eosinophil proliferation, activation, and survival. By blocking IL-5 signaling, the drug is intended to control type 2 inflammation at an upstream level and thereby reduce polyp formation and progression.
Its distinguishing feature is duration. The antibody uses Fc-region YTE technology to extend serum half-life, allowing subcutaneous administration once every six months, or only two injections per year. That makes it the longest-interval IL-5-targeting biologic described in the article and directly addresses a common adherence problem: frequent hospital visits for monthly or biweekly injections can lead to missed doses, interruption, and unstable disease control.
Evidence supporting the new indication
The Chinese approval is mainly supported by the phase III ANCHOR-1 and ANCHOR-2 studies. Together, the trials enrolled 528 patients with uncontrolled CRSwNP across 190 centers in 16 countries. Participants had bilateral nasal polyps with an endoscopic score of at least 5 and a history of surgery or ineffective or intolerable systemic corticosteroid treatment.
At week 52, 74% of patients in the depemokimab group required no additional surgery, systemic corticosteroid courses, or disease-modifying intervention, compared with 64% in the placebo group. The proportion requiring systemic corticosteroids was 26% with depemokimab and 36% with placebo. Overall tolerability was favorable, with fewer than 1% of patients discontinuing because of adverse events.
Implications for chronic disease management
For difficult-to-control CRSwNP, a twice-yearly biologic may reduce the burden of repeated surgery and systemic steroid use, while offering steadier long-term inflammatory control. It may also benefit patients with upper and lower airway comorbidity, because many CRSwNP and asthma cases share type 2 inflammatory biology.
Dr. Chen said the long-term goal in otolaryngology is to move CRSwNP treatment from repeated symptomatic rescue toward proactive disease control. Wider use of biologics could allow selected moderate-to-severe patients to receive targeted therapy earlier, rather than waiting until multiple relapses and surgical failures have already accumulated.